Sensei biotherapeutics to present new preclinical data supporting mechanism of action, pharmacokinetic profile and safety characteristics for sns-101, a conditionally active vista-blocking antibody, at the seventh cri-enci-aacr international cancer immunotherapy conference

Boston, sept. 13, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present additional preclinical data on sns-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint vista (v-domain ig suppressor of t cell activation), at the seventh annual cri-enci-aacr international cancer immunotherapy conference: translating science into survival, being held september 20 – 23, 2023 in milan, italy. the new data build on sns-101's preclinical safety and efficacy profile and provide additional insights into its conditionally active mechanism of action. sns-101 is currently in a phase 1/2 clinical study .
SNSE Ratings Summary
SNSE Quant Ranking